December 7 2021
Multiplex protein expression analysis in tissue using immunohistochemistry has rapidly evolved over the last decade from 2- and 3-plex assays to a field of new technologies enabling highly multiplexed assays of 40 or more targets. Knowing which spatial proteomic technologies would be most effective in your lab or group is difficult. In this presentation, we will walk through the value proposition for spatial proteomics, focusing on antibody- and immunohistochemistry-based spatial proteomics platforms, as well as technical review vignettes describing our lab’s experience evaluating and selecting the most appropriate media for our lab. We hope our experience can empower you on your journey into spatial proteomics.
December 7, 2021
- Understanding of spatial proteomics platforms currently available.
- Pros and cons of a select set of spatial proteomics platforms.
- Decision criteria for selecting spatial proteomics platforms based on use case and workflow.
Senior Principal Scientist
Boehringer Ingelheim Pharmaceuticals, USA
Alex Klimowicz is a Senior Principal Scientist in the Department of Immunology and Respiratory Discovery Research at Boehringer Ingelheim Pharmaceuticals, Inc. In this capacity he leads the Molecular Histopathology Group, implementing and applying cutting edge in situ techniques, whole slide imaging, and digital image analysis to deliver translational human disease data to support drug programs and define human patient segments to enable precision medicine. Alex holds a Ph.D. in Molecular Biology and has over ten years of experience in digital pathology and quantitative immunohistochemistry. Before moving to Boehringer Ingelheim, Alex was an Adjunct Research Assistant Professor in the Department of Oncology at the University of Calgary. He led a core quantitative immunohistochemistry lab focused on cancer biomarker research.